PRCA now reads as a pathogenic clue, not just a complication of leukemia
Pure red cell aplasia is no longer easy to dismiss as a downstream feature of overt T-cell large granular lymphocytic leukemia. In the Frontiers in Immunology review, the central argument is sharper: severe erythroid failure can emerge even when the circulating cytotoxic T-cell clone is small, and conventional leukemic thresholds are not met. In that setting, clone size can mislead. Pathogenicity, not abundance, becomes the more clinically useful concept.
The review places PRCA within a broader continuum that stretches from reactive cytotoxic T-cell expansion to T-cell clones of uncertain significance, low-burden clonal disease, and overt T-LGLL. The biology behind that continuum is familiar to hematologists and immunologists, but the clinical implication is more pointed here. A small clone can still suppress erythropoiesis if it carries the right antigenic specificity, survival signaling, and marrow access. In other words, the marrow can be injured before the lymphocyte count looks alarming.
Erythroid failure can appear before the clone looks “large”
The review makes a persuasive case that PRCA is a particularly clean hematologic endpoint for studying clonal cytotoxicity. Unlike vague constitutional symptoms or broad inflammatory syndromes, PRCA is defined by anemia, profound reticulocytopenia, and marked reduction or absence of erythroid precursors in an otherwise relatively preserved marrow. That narrow phenotype helps separate coincidental clonality from biologically relevant injury.
One sentence captures the clinical problem well: small clones can still behave like disease.
Several mechanisms are presented as convergent rather than competing explanations. STAT3 and broader JAK-STAT activation, apoptosis resistance, cytotoxic effector programs, antigen-driven T-cell receptor selection, marrow inflammation, and host clonal hematopoiesis all fit into the same causal frame. Persistent signaling supports survival of the cytotoxic clone; persistent effector activity keeps the erythroid compartment under pressure. The review also points to the possibility that the marrow microenvironment itself helps sustain the injury, creating a biologic setting in which erythroid progenitors are selectively vulnerable while other lineages remain comparatively spared.
Diagnosis depends on causality, not clonality alone
The review is especially useful in its warning against over-reading molecular data. Modern assays detect small clonal T-cell populations with increasing ease, including cases labeled T-cell clones of uncertain significance. TRBC1 flow cytometry and T-cell receptor sequencing can establish clonality with impressive sensitivity, yet neither test proves that the clone is responsible for a cytopenia. A detected clone may be incidental, persistent, or pathogenic depending on the clinical context.
Causal attribution therefore has to be built step by step. Confirmed PRCA comes first, followed by careful exclusion of competing causes. Immunophenotype, TCR clonality, and molecular findings are then interpreted together rather than in isolation. The review also cautions that low variant allele frequency STAT3 mutations in unsorted blood or marrow can be difficult to interpret because lymphoid and age-related myeloid clones may coexist in the same sample. A mutation is informative only when the lineage carrying it is understood.
This is where the review’s framework is most practical. It treats a small clone with severe erythroid failure as potentially meaningful even when the case does not satisfy historical numeric thresholds for leukemia. The patient’s marrow does not care whether the clone crosses a historical cut point. It cares whether erythropoiesis is being suppressed.
PRCA may be the first visible sign of a pathogenic T-cell clone
The review draws on cohort data suggesting that PRCA can precede overt recognition of T-LGLL. STAT3-mutated CD8-positive T-cell clones have been identified in acquired PRCA, including patients who did not meet conventional T-LGLL criteria. Other studies described clonal T-cell expansion and STAT3 mutations in chronic T-cell-mediated PRCA, supporting a spectrum from oligoclonal immune dysregulation to manifest clonal cytotoxic disease.
Population-level data from Korea add a useful epidemiologic layer: in patients with both PRCA and T-LGL, PRCA often came first or appeared at the same time, while T-LGL rarely preceded PRCA. Administrative data cannot prove direct cellular causality, and the review is careful about that point. Still, the pattern supports a familiar bedside observation: the erythroid compartment may declare itself early, before a larger clonal population becomes obvious in blood.
Immunosuppression remains central, but the target has changed
Therapy in this framework is still anchored by cyclosporine and cyclophosphamide, with methotrexate positioned as a phenotype-dependent option. Refractory disease may justify sirolimus or JAK inhibition, because those strategies align more directly with the biology of persistent survival signaling and cytokine-driven cytotoxicity. The logic is straightforward: if the clone survives through activated intracellular signaling, suppressing those pathways becomes rational.
What matters clinically is not simply whether the clone shrinks on paper. The relevant endpoint is restoration of erythropoiesis and durable transfusion independence. A patient can carry residual clonality and still have meaningful hematologic recovery. That focus on erythroid response instead of molecular eradication is one of the review’s most useful corrections to older thinking.
One sentence stands out in practice: treatment should follow the cytopenia, not the clone count.
Why this review matters for hematology practice
The review’s broader contribution is conceptual. It replaces a rigid leukemia-versus-benign dichotomy with a model centered on clonal pathogenicity. Reactive expansion, T-CUS, low-burden disease, and overt T-LGLL are presented as biologically related states rather than isolated boxes, and PRCA is used as the clinical event that reveals when a clone has crossed into pathogenic territory. That framing is likely to be especially useful for patients who look borderline by count but clearly abnormal by marrow consequence.
The limitations are real. Much of the evidence base still comes from retrospective cohorts, small prospective studies, and older series that predate current flow cytometry and molecular methods. Response definitions are inconsistent, especially for transfusion independence, hemoglobin recovery, and clonal response. Treatment selection is also confounded by phenotype, comorbidity, and prior therapy, making head-to-head comparisons difficult. The review argues for clone-resolved multi-omics, standardized response endpoints, and prospective molecularly stratified registries to resolve those gaps.
For now, the practical message is direct: in PRCA associated with clonal cytotoxic T cells, the important question is not whether the clone is large enough to satisfy an old numeric threshold. The important question is whether it is biologically capable of shutting down erythropoiesis.
Citation to this review
The article calls for future studies that can separate clone presence from clone effect, especially in patients whose marrow failure is disproportionate to lymphocyte burden. Until those data arrive, clinicians will have to keep making decisions with incomplete molecular visibility and a heavy reliance on phenotype, lineage attribution, and treatment response.
- • Frontiers in Immunology review DOI 10.3389/fimmu.2026.1997692: https://doi.org/10.3389/fimmu.2026.1997692